Nabriva Therapeutics — Investor Presentation (November 2015)
17 slides from Nabriva Therapeutics's investor presentation, Nov 10, 2015

Slide 1: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, future financi

Slide 2: Colin Broom, MD, Chief Executive Officer
3 Colin Broom, MD Chief Executive Officer Nabriva Therapeutics AG

Slide 3: Nabriva Corporate Strategy
Nabriva Corporate Strategy Become a Fully Integrated Company Focused on Novel Antibiotics for Serious Infections Complete Phase 3 trials and obtain regulatory approval of lefamulin for Community Acquired Bacterial Pneumonia (CABP) Maximize the commercial potential of lefamulin for CABP Pursue the de

Slide 4: Lefamulin 2015 Highlights
Lefamulin 2015 Highlights Pleuromutilins – new class of antibiotics in development for systemic use in humans Novel mechanism of action with potent in vitro activity against multi-drug resistant strains Proprietary platform and IP wholly owned by Nabriva with extensive in-house expertise Lefamulin -

Slide 5: Nabriva's Pleuromutilin Pipeline is Advancing
Nabriva’s Pleuromutilin Pipeline is Advancing Program Indications Discovery Pre-clinical Phase 1 Phase 2 Phase 3 Comments Lefamulin (IV/oral) CABP* IV/Oral Phase 3 initiated; Oral Phase 3 initiation planned 1Q16 ABSSSI Phase 2 complete Lefamulin (IV/oral) Pediatric Indications Preclinical work and f

Slide 6: Elyse Seltzer, MD, Chief Medical Officer
7 Elyse Seltzer, MD Chief Medical Officer Nabriva Therapeutics AG

Slide 7: Clinical Development Plan for Differentiation in CABP
Clinical Development Plan for Differentiation in CABP Phase 3 CABP registration program initiated in the fall of 2015 Lefamulin Evaluation Against Pneumonia (LEAP) trial (IV to oral) in patients with moderate-to-severe CABP (PORT III and above) Second study (oral) in moderate CABP (PORT II to IV) Ex

Slide 8: LEAP IV to Oral Powering and Primary Objectives
LEAP IV to Oral Powering and Primary Objectives LEAP has 90% power to establish the non-inferiority (NI) of lefamulin to moxifloxacin for both FDA and EMA endpoints using a NI margin of 10% Demonstrate the NI of lefamulin versus comparator with respect to Early Clinical Response , (96 ± 24 hours aft

Slide 9: LEAP IV to Oral Trial Design
LEAP IV to Oral Trial Design Phase 3: Double-blind, double-dummy; active-controlled Population Approximately 740 adult patients with CABP Pneumonia Outcomes Research Team (PORT) Risk Class >III (moderate to severe) Approximately 100 international centers 1:1 randomization - lefamulin v comparator (m

Slide 10: LEAP IV to Oral Treatment Scenarios
LEAP IV to Oral Treatment Scenarios All subjects begin with IV therapy for a minimum of three days before switching to oral therapy Majority of patients will receive 5 days of lefamulin v 7 days moxifloxacin If CABP caused by 1) S. pneumoniae with accompanying bacteremia or 2) L. pneumophila, both t

Slide 11: LEAP IV to Oral Switch Criteria
LEAP IV to Oral Switch Criteria Subjects will be permitted to switch from IV to oral study drug if all of the following criteria are met: Have received 3 days (6 doses) of IV therapy Are hemodynamically stable Have a normalizing temperature Have demonstrated improvement in at least 1 severity catego

Slide 12: Ralf Schmid, Chief Operating Officer and Chief Financial Officer
13 Ralf Schmid Chief Operating Officer and Chief Financial Officer Nabriva Therapeutics AG

Slide 13: Initial Public Offering of American Depositary Shares Completed in September 2015
Initial Public Offering of American Depositary Shares (NASDAQ:NBRV) Completed in September 2015 We sold a total of 10,350,000 ADSs at an offering price of $10.25 per ADS Each ADS represents one tenth (1/10) of a common share 2,098,972 common shares outstanding on September 30, 2015 Upon the closing

Slide 14: Colin Broom, MD, Chief Executive Officer
16 Colin Broom, MD Chief Executive Officer Nabriva Therapeutics AG

Slide 15: Anticipated Key Milestones
Anticipated Key Milestones October 2015: First Phase 3 clinical trial for the treatment of CABP initiated 1Q 2016: Second Phase 3 clinical trial for the treatment of CABP to be initiated 2H 2017: Top-line data available for both Phase 3 trials for the treatment of CABP 2018: Submission of a NDA to t

Slide 16: Nabriva Summary
Nabriva Summary Developing novel antibiotics for serious infections Pleuromutilins – new class of antibiotics in development for systemic use in humans Novel mechanism of action with potent in vitro activity against multi-drug resistant strains Proprietary platform and IP wholly owned by Nabriva wit

Slide 17: Nabriva Summary
Nabriva Summary = Developing novel antibiotics for serious infections = Pleuromutilins — new class of antibiotics in development for systemic use in humans + Novel mechanism of action with potent in vitro activity against multi-drug resistant strains + Proprietary platform and IP wholly owned by Nab
Source: SEC EDGAR · 6-K filed Nov 10, 2015
More decks from Nabriva Therapeutics AG
Investor Presentation (April 2021)30 slides · Apr 15, 2021
Q3 2019 Earnings Presentation27 slides · Nov 12, 2019
Technical Presentation (May 2018)36 slides · May 21, 2018
Investor Presentation (November 2017)57 slides · Nov 7, 2017
Conference Presentation (September 2017)28 slides · Sep 18, 2017
Investor Day (June 2017)49 slides · Jun 19, 2017